ALIX: ALG-2-interacting protein X; CD9, CD63, CD81: cluster of differentiation 9, 63 and 81; TSG101: tumour susceptibility gene 101.
Declarations
Acknowledgments
During the preparation of this work, the author(s) used Grammarly to correct grammatical and language errors. After utilizing the tool, the author(s) reviewed and edited the content as necessary.
Author contributions
MH: Conceptualization, Investigation, Validation, Supervision, Writing—original draft, Writing—review & editing. SF, KS & AS: Investigation, Validation, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no competing interests. Dr Khadija Shakoor and Dr Abdul Shakoor share a common surname; they are not related and the shared surname is coincidental. This relationship had no bearing upon the design, conduct or reporting of this review, and the authors declare that it gives rise to no competing interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
All data discussed in this review are available in the cited published sources.
Funding
Not applicable. This work received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology. 2023;77:1335–47. [DOI] [PubMed] [PMC]
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology. 2016;64:73–84. [DOI] [PubMed]
Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD.Trends Endocrinol Metab. 2024;35:697–707. [DOI] [PubMed]
Younossi ZM, Razavi H, Sherman M, Allen AM, Anstee QM, Cusi K, et al. Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction-Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective.Aliment Pharmacol Ther. 2025;61:1467–78. [DOI] [PubMed]
Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.Gut. 2024;73:691–702. [DOI] [PubMed]
Kalligeros M, Henry L, Younossi ZM. Metabolic dysfunction-associated steatotic liver disease and its link to cancer.Metabolism. 2024;160:156004. [DOI] [PubMed]
Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-Järvinen H, et al. Metabolic dysfunction-associated steatotic liver disease in adults.Nat Rev Dis Primers. 2025;11:14. [DOI] [PubMed]
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).J Hepatol. 2024;81:492–542. [DOI] [PubMed]
Tilg H, Petta S, Stefan N, Targher G. Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: a review.JAMA. 2026;335:163–74. [DOI] [PubMed]
Khan MS, Javaid SS, Dinani A, Wegermann K, Pandey A, Bhatt AS, et al. The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists: pathophysiology, diagnosis, and treatment.J Am Coll Cardiol. 2025;86:1861–84. [DOI] [PubMed]
Mustafa A, Kite C, Lagojda L, Dallaway A, Chatha KK, Than NN, et al. Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review.Int J Mol Sci. 2025;26:11275. [DOI] [PubMed] [PMC]
Brown MS, Goldstein JL. Selective versus Total Insulin Resistance: A Pathogenic Paradox.Cell Metab. 2008;7:95–6. [DOI] [PubMed]
Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome.Proc Natl Acad Sci. 2007;104:12587–94. [DOI] [PubMed] [PMC]
Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance.Physiol Rev. 2018;98:2133–223. [DOI] [PubMed] [PMC]
Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Ng ZC, et al. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies.World J Diabetes. 2026;17:113149. [DOI] [PubMed] [PMC]
Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders.Nature. 2017;542:177–85. [DOI] [PubMed]
Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches.J Extracell Vesicles. 2024;13:e12404. [DOI] [PubMed] [PMC]
van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles.Nat Rev Mol Cell Biol. 2018;19:213–28. [DOI] [PubMed]
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes.Science. 2020;367:eaau6977. [DOI] [PubMed] [PMC]
Dixson AC, Dawson TR, Di Vizio D, Weaver AM. Context-specific regulation of extracellular vesicle biogenesis and cargo selection.Nat Rev Mol Cell Biol. 2023;24:454–76. [DOI] [PubMed] [PMC]
Carvalho Ferraz L, Pereira P, Ferreira JV. Molecular Mechanisms of Extracellular Vesicle Biogenesis and Their Impact on the Design of Custom EVs.Adv Healthc Mater. 2025;14:e2501349. [DOI] [PubMed] [PMC]
Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.J Extracell Vesicles. 2018;7:1535750. [DOI] [PubMed] [PMC]
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.J Hepatol. 2023;79:1542–56. [DOI] [PubMed]
Lei Y, Liu M, Tao X. Extracellular Vesicles: Orchestrators of Intrahepatic and Systemic Crosstalk in Metabolic Dysfunction-Associated Steatotic Liver Disease.Pharmaceutics. 2026;18:116. [DOI] [PubMed] [PMC]
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.Hepatology. 2023;77:1797–835. [DOI] [PubMed] [PMC]
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.J Hepatol. 2020;73:202–9. [DOI] [PubMed]
Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.Gastroenterology. 2020;158:1999–2014.e1. [DOI] [PubMed]
Colombo M, Raposo G, Théry C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles.Annu Rev Cell Dev Biol. 2014;30:255–89. [DOI] [PubMed]
Juan T, Fürthauer M. Biogenesis and function of ESCRT-dependent extracellular vesicles.Semin Cell Dev Biol. 2018;74:66–77. [DOI] [PubMed]
Wollert T, Hurley JH. Molecular mechanism of multivesicular body biogenesis by ESCRT complexes.Nature. 2010;464:864–9. [DOI] [PubMed] [PMC]
Wollert T, Wunder C, Lippincott-Schwartz J, Hurley JH. Membrane scission by the ESCRT-III complex.Nature. 2009;458:172–7. [DOI] [PubMed] [PMC]
Schöneberg J, Pavlin MR, Yan S, Righini M, Lee IH, Carlson LA, et al. ATP-dependent force generation and membrane scission by ESCRT-III and Vps4.Science. 2018;362:1423–8. [DOI] [PubMed] [PMC]
Quinney KB, Frankel EB, Shankar R, Kasberg W, Luong P, Audhya A. Growth factor stimulation promotes multivesicular endosome biogenesis by prolonging recruitment of the late-acting ESCRT machinery.Proc Natl Acad Sci U S A. 2019;116:6858–67. [DOI] [PubMed] [PMC]
Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. Syndecan–syntenin–ALIX regulates the biogenesis of exosomes.Nat Cell Biol. 2012;14:677–85. [DOI] [PubMed]
Fukushima M, Dasgupta D, Mauer AS, Kakazu E, Nakao K, Malhi H. StAR-related lipid transfer domain 11 (STARD11)–mediated ceramide transport mediates extracellular vesicle biogenesis.J Biol Chem. 2018;293:15277–89. [DOI] [PubMed] [PMC]
Kakazu E, Mauer AS, Yin M, Malhi H. Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1α-dependent manner.J Lipid Res. 2016;57:233–45. [DOI] [PubMed] [PMC]
Hochreuter MY, Dall M, Treebak JT, Barrès R. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.Mol Metab. 2022;65:101581. [DOI] [PubMed] [PMC]
Thomou T, Mori MA, Dreyfuss JM, Konishi M, Sakaguchi M, Wolfrum C, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues.Nature. 2017;542:450–5. [DOI] [PubMed] [PMC]
Kranendonk ME, Visseren FL, van Herwaarden JA, Nolte-'t Hoen EN, de Jager W, Wauben MH, et al. Effect of extracellular vesicles of human adipose tissue on insulin signaling in liver and muscle cells.Obesity (Silver Spring). 2014;22:2216–23. [DOI] [PubMed]
Castaño C, Kalko S, Novials A, Párrizas M. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice.Proc Natl Acad Sci U S A. 2018;115:12158–63. [DOI] [PubMed] [PMC]
Zhao R, Zhao T, He Z, Cai R, Pang W. Composition, isolation, identification and function of adipose tissue-derived exosomes.Adipocyte. 2021;10:587–604. [DOI] [PubMed] [PMC]
Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, Seo JB, et al. Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity.Cell. 2017;171:372–84.e12. [DOI] [PubMed]
Whitham M, Parker BL, Friedrichsen M, Hingst JR, Hjorth M, Hughes WE, et al. Extracellular Vesicles Provide a Means for Tissue Crosstalk during Exercise.Cell Metab. 2018;27:237–51.e4. [DOI] [PubMed]
Zhang Y, Wei Q, Geng X, Fang G. Long-Term Aerobic Exercise Enhances Hepatoprotection in MAFLD by Modulating Exosomal miR-324 via ROCK1.Metabolites. 2024;14:692. [DOI] [PubMed] [PMC]
Zhao Y, Gao L, Chen J, Wei J, Lin G, Hu K, et al. Remote limb ischemic conditioning alleviates steatohepatitis via extracellular vesicle-mediated muscle-liver crosstalk.Cell Metab. 2025;37:886–902.e7. [DOI] [PubMed]
Zhao Y, Zhao MF, Jiang S, Wu J, Liu J, Yuan XW, et al. Liver governs adipose remodelling via extracellular vesicles in response to lipid overload.Nat Commun. 2020;11:719. [DOI] [PubMed] [PMC]
Alén R, Garcia-Martinez I, Cobo-Vuilleumier N, Fernández-Millán E, Gallardo-Villanueva P, Ferreira V, et al. Effect of lipotoxic hepatocyte-derived extracellular vesicles in pancreas inflammation: essential role of macrophage TLR4 in beta cell functionality.Diabetologia. 2025;68:1801–22. [DOI] [PubMed] [PMC]
Liao CY, Song MJ, Gao Y, Mauer AS, Revzin A, Malhi H. Hepatocyte-Derived Lipotoxic Extracellular Vesicle Sphingosine 1-Phosphate Induces Macrophage Chemotaxis.Front Immunol. 2018;9:2980. [DOI] [PubMed] [PMC]
Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Werneburg NW, et al. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.Gastroenterology. 2016;150:956–67. [DOI] [PubMed] [PMC]
Ibrahim SH, Hirsova P, Tomita K, Bronk SF, Werneburg NW, Harrison SA, et al. Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10–bearing chemotactic extracellular vesicles from lipotoxic hepatocytes.Hepatology. 2016;63:731–44. [DOI] [PubMed] [PMC]
Tomita K, Freeman BL, Bronk SF, LeBrasseur NK, White TA, Hirsova P, et al. CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis.Sci Rep. 2016;6:28786. [DOI] [PubMed] [PMC]
Liu XL, Pan Q, Cao HX, Xin FZ, Zhao ZH, Yang RX, et al. Lipotoxic Hepatocyte-Derived Exosomal MicroRNA 192-5p Activates Macrophages Through Rictor/Akt/Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease.Hepatology. 2020;72:454–69. [DOI] [PubMed] [PMC]
Liu H, Niu Q, Wang T, Dong H, Bian C. Lipotoxic hepatocytes promote nonalcoholic fatty liver disease progression by delivering microRNA-9-5p and activating macrophages.Int J Biol Sci. 2021;17:3745–59. [DOI] [PubMed] [PMC]
Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, de Araujo Horcel L, et al. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ.Cell Mol Gastroenterol Hepatol. 2015;1:646–63.e4. [DOI] [PubMed] [PMC]
Lee YS, Kim SY, Ko E, Lee JH, Yi HS, Yoo YJ, et al. Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells.Sci Rep. 2017;7:3710. [DOI] [PubMed] [PMC]
Jiang F, Chen Q, Wang W, Ling Y, Yan Y, Xia P. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1.J Hepatol. 2020;72:156–66. [DOI] [PubMed]
Tarantino G, Citro V. Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications.World J Gastroenterol. 2026;32:119467. [DOI]
Dasgupta D, Nakao Y, Mauer AS, Thompson JM, Sehrawat TS, Liao CY, et al. IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis.Gastroenterology. 2020;159:1487–503.e17. [DOI] [PubMed] [PMC]
Momen-Heravi F, Bala S, Kodys K, Szabo G. Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS.Sci Rep. 2015;5:9991. [DOI] [PubMed] [PMC]
Das A, Basu S, Bandyopadhyay D, Mukherjee K, Datta D, Chakraborty S, et al. Inhibition of extracellular vesicle-associated MMP2 abrogates intercellular hepatic miR-122 transfer to liver macrophages and curtails inflammation.iScience. 2021;24:103428. [DOI] [PubMed] [PMC]
He Y, Rodrigues RM, Wang X, Seo W, Ma J, Hwang S, et al. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223–enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis.J Clin Invest. 2021;131:e141513. [DOI] [PubMed] [PMC]
Hou X, Yin S, Ren R, Liu S, Yong L, Liu Y, et al. Myeloid-Cell–Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.Hepatology. 2021;74:116–32. [DOI] [PubMed] [PMC]
Zhang M, Li K, Huang X, Xu D, Zong R, Hu Q, et al. Macrophage Notch1 signaling modulates regulatory T cells via the TGFB axis in early MASLD.JHEP Rep. 2025;7:101242. [DOI] [PubMed] [PMC]
Thietart S, Rautou PE. Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view.J Hepatol. 2020;73:1507–25. [DOI] [PubMed]
Szabo G, Momen-Heravi F. Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets.Nat Rev Gastroenterol Hepatol. 2017;14:455–66. [DOI] [PubMed] [PMC]
Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.Gut. 2014;64:800–12. [DOI] [PubMed] [PMC]
Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, et al. Circulating Extracellular Vesicles with Specific Proteome and Liver MicroRNAs Are Potential Biomarkers for Liver Injury in Experimental Fatty Liver Disease.PLoS ONE. 2014;9:e113651. [DOI] [PubMed] [PMC]
Sakane S, Hikita H, Shirai K, Sakamoto T, Narumi R, Adachi J, et al. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.Hepatol Commun. 2024;8:e0448. [DOI] [PubMed] [PMC]
Do A, Zahrawi F, Mehal WZ. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).Nat Rev Drug Discov. 2025;24:171–89. [DOI] [PubMed]
Chen Y, Yang F, Wang Y, Shi Y, Liu L, Luo W, et al. Mesenchymal stem cell-derived small extracellular vesicles reduced hepatic lipid accumulation in MASLD by suppressing mitochondrial fission.Stem Cell Res Ther. 2025;16:116. [DOI] [PubMed] [PMC]
Povero D, Pinatel EM, Leszczynska A, Goyal NP, Nishio T, Kim J, et al. Human induced pluripotent stem cell–derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis.JCI Insight. 2019;5:e125652. [DOI] [PubMed] [PMC]
Huai Q, Zhu C, Zhang X, Dai H, Li X, Wang H. Mesenchymal stromal/stem cells and their extracellular vesicles in liver diseases: insights on their immunomodulatory roles and clinical applications.Cell Biosci. 2023;13:162. [DOI] [PubMed] [PMC]
Kostallari E, Valainathan S, Biquard L, Shah VH, Rautou PE. Role of extracellular vesicles in liver diseases and their therapeutic potential.Adv Drug Deliv Rev. 2021;175:113816. [DOI] [PubMed] [PMC]
Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes.Proc Natl Acad Sci U S A. 2014;111:14888–93. [DOI] [PubMed] [PMC]